Pharmacogenomics and Pharmacogenetics of Thiazolidinediones: Role in Diabetes and Cardiovascular Risk Factors
Year: 2014
Type: article
Abstract: The most important goal in the treatment of patients with diabetes is to prevent the risk of cardiovascular disease (CVD), the first cause of mortality in these subjects. Thiazolidinediones (TZDs), a class of antidiabetic drugs, act as insulin sensitizers increasing insulin-dependent glucose disposal and reducing hepatic glucose output. TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-γ have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis. However, troglitazone was removed from the market due to its hepatoxicity, and rosiglitazone and pioglitazone both have particular warnings due to being associated with heart diseases. Specific genetic variations in genes involved in the pathways regulated by TDZs have demonstrated to modify the variability in treatment with these drugs, especially in their side effects. Therefore, pharmacogenomics and pharmacogenetics are an important tool in further understand intersubject variability per se but also to assess the therapeutic potential of such variability in drug individualization and therapeutic optimization.
Source: Pharmacogenomics
DOI: 10.2217/pgs.14.162
Authors: David Della-Morte, Raffaele Palmirotta, Ashish K Rehni, Donatella Pastore, Barbara Capuani, Francesca Pacifici, Maria Laura De Marchis, Kunjan R Dave, Alfonso Bellia, Giuseppe Fogliame, Patrizia Ferroni, Giulia Donadel, Francesco Cacciatore, Pasquale Abete, Chuanhui Dong, Antonello Pileggi, Mario Roselli, Camillo Ricordi, Paolo Sbraccia, Fiorella Guadagni, Tatjana Rundek, Davide Lauro
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
Awards: G6434404564, G8314384578, G9000201445
OpenAlex ID: W2169752693